Engitix Therapeutics: Valuation, Funding & Investors
Engitix Therapeutics is a biotechnology company that discovers and develops novel therapeutics by targeting the extracellular matrix (ECM) and ECM-mediated biology. The company applies proprietary ECM proteomics and decellularized-matrix discovery platforms to identify disease-associated matrix components and to advance therapeutic candidates and biomarkers for oncology and fibrotic diseases.
Leadership & Board
- Current Number of Employees
- 65
- Current LinkedIn Followers
- 10,101
Latest Estimated Valuation
- Total Amount Raised
- $54M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $54M
- Latest Funding Round
- Series A
Employee Trend
Engitix Therapeutics had 65 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Engitix Therapeutics had 10,101 followers as of November 9, 2026. The number of followers increased by 75 (0.75%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Feb 19, 2022 | Series A | $54.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Netherton Investments | Series A |
| DOMPE | Series A |
Similar Companies
A snapshot of private companies similar to Engitix Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis








